Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Get this document free

Rheumatoid Arthritis – Pipeline Review, H1 2012

VIEWS: 12 PAGES: 348

Rheumatoid Arthritis - Pipeline Review, H1 2012', provides an overview of the Rheumatoid Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. 'Rheumatoid Arthritis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
									          Rheumatoid Arthritis – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1731IDB
                                                                                           Publication Date: February 2012




Rheumatoid Arthritis – Pipeline Review, H1 2012                                            GMDHC1731IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Rheumatoid Arthritis – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ............................................................................................................................................................................... 10
    List of Figures .............................................................................................................................................................................. 16
Introduction....................................................................................................................................................................................... 17
    Global Markets Direct Report Coverage ...................................................................................................................................... 17
Rheumatoid Arthritis Overview ......................................................................................................................................................... 18
Therapeutics Development............................................................................................................................................................... 19
    An Overview of Pipeline Products for Rheumatoid Arthritis ......................................................................................................... 19
Rheumatoid Arthritis Therapeutics under Development by Companies ........................................................................................... 21
Rheumatoid Arthritis Therapeutics under Investigation by Universities/Institutes............................................................................. 36
Late Stage Products ......................................................................................................................................................................... 39
    Comparative Analysis .................................................................................................................................................................. 39
Mid Clinical Stage Products.............................................................................................................................................................. 40
    Comparative Analysis .................................................................................................................................................................. 40
Early Clinical Stage Products ........................................................................................................................................................... 41
    Comparative Analysis .................................................................................................................................................................. 41
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 42
    Comparative Analysis .................................................................................................................................................................. 42
Rheumatoid Arthritis Therapeutics – Products under Development by Companies ......................................................................... 43
Rheumatoid Arthritis Therapeutics – Products under Investigation by Universities/Institutes........................................................... 62
Companies Involved in Rheumatoid Arthritis Therapeutics Development ........................................................................................ 64
    Bristol-Myers Squibb Company ................................................................................................................................................... 64
    Johnson & Johnson ..................................................................................................................................................................... 65
    Boehringer Ingelheim GmbH ....................................................................................................................................................... 66
    F. Hoffmann-La Roche Ltd. ......................................................................................................................................................... 67
    Biogen Idec Inc. ........................................................................................................................................................................... 68
    Amgen Inc. .................................................................................................................................................................................. 69
    AstraZeneca PLC ........................................................................................................................................................................ 70
    Eli Lilly and Company .................................................................................................................................................................. 71
    GlaxoSmithKline plc .................................................................................................................................................................... 72
    Genentech, Inc. ........................................................................................................................................................................... 73
    Inovio Biomedical Corporation ..................................................................................................................................................... 74
    MedImmune LLC ......................................................................................................................................................................... 75
    Isis Pharmaceuticals, Inc. ............................................................................................................................................................ 76
    Biotest AG ................................................................................................................................................................................... 77
    Merck & Co., Inc. ......................................................................................................................................................................... 78
    Santen Pharmaceutical Co., Ltd. ................................................................................................................................................. 79
    Ablynx .......................................................................................................................................................................................... 80
    Micromet, Inc. .............................................................................................................................................................................. 81
    Novo Nordisk A/S ........................................................................................................................................................................ 82
    Plexxikon Inc. .............................................................................................................................................................................. 83
    BioLineRx, Ltd. ............................................................................................................................................................................ 84



Rheumatoid Arthritis – Pipeline Review, H1 2012                                                                                             GMDHC1731IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                    Page(2)
Rheumatoid Arthritis – Pipeline Review, H1 2012




    arGentis Pharmaceuticals, LLC ................................................................................................................................................... 85
    MediGene AG .............................................................................................................................................................................. 86
    Celltrion, Inc................................................................................................................................................................................. 87
    TiGenix NV .................................................................................................................................................................................. 88
    Pacira Pharmaceuticals, Inc. ....................................................................................................................................................... 89
    Novartis AG ................................................................................................................................................................................. 90
    Astellas Pharma Inc..................................................................................................................................................................... 91
    Biocon Limited ............................................................................................................................................................................. 92
    Daewoong Pharmaceutical Co., Ltd. ........................................................................................................................................... 93
    Dong-A Pharmaceutical Co., Ltd. ................................................................................................................................................ 94
    Glenmark Pharmaceuticals Ltd.................................................................................................................................................... 95
    Maxygen, Inc. .............................................................................................................................................................................. 96
    Mitsubishi Tanabe Pharma Corporation ...................................................................................................................................... 97
    Pfizer Inc...................................................................................................................................................................................... 98
    Rigel Pharmaceuticals, Inc. ......................................................................................................................................................... 99
    Santarus, Inc. ............................................................................................................................................................................ 100
    Teva Pharmaceutical Industries Limited .................................................................................................................................... 101
    Toyama Chemical Co. Ltd ......................................................................................................................................................... 102
    Vertex Pharmaceuticals Incorporated........................................................................................................................................ 103
    Zydus Cadila Healthcare Limited ............................................................................................................................................... 104
    Genmab A/S .............................................................................................................................................................................. 105
    novosom AG .............................................................................................................................................................................. 106
    CEL-SCI Corporation................................................................................................................................................................. 107
    Celgene Corporation ................................................................................................................................................................. 108
    Onyx Pharmaceuticals, Inc. ....................................................................................................................................................... 109
    Incyte Corporation ..................................................................................................................................................................... 110
    Vernalis plc ................................................................................................................................................................................ 111
    Merck KGaA .............................................................................................................................................................................. 112
    Bone Medical Limited ................................................................................................................................................................ 113
    4SC AG ..................................................................................................................................................................................... 114
    3SBio Inc. .................................................................................................................................................................................. 115
    Addex Pharmaceuticals ............................................................................................................................................................. 116
    EntreMed, Inc. ........................................................................................................................................................................... 117
    Evotec Aktiengesellschaft.......................................................................................................................................................... 118
    Genesis Research and Development Corporation Ltd. ............................................................................................................. 119
    GW Pharmaceuticals plc ........................................................................................................................................................... 120
    Hollis-Eden Pharmaceuticals, Inc. ............................................................................................................................................. 121
    IMMUNOMEDICS, INC ............................................................................................................................................................. 122
    Can-Fite BioPharma Ltd. ........................................................................................................................................................... 123
    Idera Pharmaceuticals, Inc. ....................................................................................................................................................... 124
    Karo Bio..................................................................................................................................................................................... 125
    Almirall, S.A. .............................................................................................................................................................................. 126
    Lupin Limited ............................................................................................................................................................................. 127
    Medivir AB ................................................................................................................................................................................. 128


Rheumatoid Arthritis – Pipeline Review, H1 2012                                                                                             GMDHC1731IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(3)
Rheumatoid Arthritis – Pipeline Review, H1 2012




    PROLOR Biotech, Inc................................................................................................................................................................ 129
    Novogen Limited........................................................................................................................................................................ 130
    Nutra Pharma Corporation ........................................................................................................................................................ 131
    Compugen Ltd. .......................................................................................................................................................................... 132
    Lexicon Pharmaceuticals, Inc. ................................................................................................................................................... 133
    Accentia Biopharmaceuticals, Inc. ............................................................................................................................................. 134
    Portola Pharmaceuticals, Inc. .................................................................................................................................................... 135
    Chelsea Therapeutics, Inc. ........................................................................................................................................................ 136
    CombinatoRx, Incorporated ....................................................................................................................................................... 137
    Yuhan Corporation .................................................................................................................................................................... 138
    Zenotech Laboratories Limited .................................................................................................................................................. 139
    Regeneron Pharmaceuticals, Inc............................................................................................................................................... 140
    Unigene Laboratories, Inc. ........................................................................................................................................................ 141
    Pharmacyclics, Inc..................................................................................................................................................................... 142
    Protalix BioTherapeutics, Inc. .................................................................................................................................................... 143
    Tolerx, Inc. ................................................................................................................................................................................. 144
    Antisoma plc .............................................................................................................................................................................. 145
    MorphoSys AG .......................................................................................................................................................................... 146
    Boryung Pharmaceutical Co., Ltd. ............................................................................................................................................. 147
    Hanall Pharmaceutical Co., Ltd. ................................................................................................................................................ 148
    LG Life Sciences, Ltd ............................................................................................................................................................... 149
    AnGes MG, Inc. ......................................................................................................................................................................... 150
    Biotie Therapies Corp. ............................................................................................................................................................... 151
    Transition Therapeutics Inc. ...................................................................................................................................................... 152
    LTT Bio-Pharma Co., Ltd........................................................................................................................................................... 153
    Galapagos NV ........................................................................................................................................................................... 154
    Synta Pharmaceuticals Corp. .................................................................................................................................................... 155
    CrystalGenomics, Inc. ............................................................................................................................................................... 156
    Sareum Holdings plc ................................................................................................................................................................. 157
    Protalex, Inc............................................................................................................................................................................... 158
    Proximagen Neuroscience plc. .................................................................................................................................................. 159
    Newron Pharmaceuticals S.p.A. ................................................................................................................................................ 160
    Simcere Pharmaceutical Group ................................................................................................................................................. 161
    Piramal Life Sciences Limited.................................................................................................................................................... 162
    Morphotek, Inc. .......................................................................................................................................................................... 163
    Chroma Therapeutics Ltd. ......................................................................................................................................................... 164
    Advinus Therapeutics Pvt. Ltd. .................................................................................................................................................. 165
    Affimed Therapeutics AG .......................................................................................................................................................... 166
    Ambit Biosciences Corporation.................................................................................................................................................. 167
    AnaMar Medical AB ................................................................................................................................................................... 168
    Viron Therapeutics, Inc.............................................................................................................................................................. 169
    Immupharma Plc ....................................................................................................................................................................... 170
    Palau Pharma S.A ..................................................................................................................................................................... 171
    Philogen S.p.A. .......................................................................................................................................................................... 172


Rheumatoid Arthritis – Pipeline Review, H1 2012                                                                                            GMDHC1731IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(4)
Rheumatoid Arthritis – Pipeline Review, H1 2012




    Probiodrug AG ........................................................................................................................................................................... 173
    Acceleron Pharma, Inc. ............................................................................................................................................................. 174
    Phenex Pharmaceuticals AG ..................................................................................................................................................... 175
    Neovacs SA ............................................................................................................................................................................... 176
    MIKA Pharma GmbH ................................................................................................................................................................. 177
    CREABILIS Therapeutics S.r.l. .................................................................................................................................................. 178
    Artielle ImmunoTherapeutics, Inc. ............................................................................................................................................. 179
    Aquinox Pharmaceuticals Inc. ................................................................................................................................................... 180
    Amura Holdings Ltd. .................................................................................................................................................................. 181
    JADO Technologies GmbH. ...................................................................................................................................................... 182
    AnaptysBio, Inc.......................................................................................................................................................................... 183
    IMMD Inc. .................................................................................................................................................................................. 184
    Circassia Holdings Ltd. .............................................................................................................................................................. 185
    Funxional Therapeutics Ltd ....................................................................................................................................................... 186
    Oxagen Limited ......................................................................................................................................................................... 187
    Catabasis Pharmaceuticals, Inc. ............................................................................................................................................... 188
    Recoly N.V................................................................................................................................................................................. 189
    Opsona Therapeutics Ltd. ......................................................................................................................................................... 190
    Asahi Kasei Pharma .................................................................................................................................................................. 191
    Vaccinex, Inc. ............................................................................................................................................................................ 192
    Syntrix Biosystems, Inc. ............................................................................................................................................................ 193
    Peptimmune, Inc........................................................................................................................................................................ 194
    S*BIO Pte Ltd ............................................................................................................................................................................ 195
    Deciphera Pharmaceuticals, LLC .............................................................................................................................................. 196
    Indus Biotech Private Limited .................................................................................................................................................... 197
    NovImmune SA ......................................................................................................................................................................... 198
    Txcell SA ................................................................................................................................................................................... 199
    Theraclone Sciences, Inc. ......................................................................................................................................................... 200
    Theracos, Inc. ............................................................................................................................................................................ 201
    TcL Pharma SAS ....................................................................................................................................................................... 202
    Versartis, Inc.............................................................................................................................................................................. 203
    Cardax Pharmaceuticals, Inc. .................................................................................................................................................... 204
    Virobay Inc................................................................................................................................................................................. 205
    Myriad Pharmaceuticals, Inc...................................................................................................................................................... 206
    Inimex Pharmaceuticals, Inc. ..................................................................................................................................................... 207
    Karus Therapeutics Ltd ............................................................................................................................................................. 208
    Logical Therapeutics, Inc........................................................................................................................................................... 209
    Omeros Corporation .................................................................................................................................................................. 210
    Xencor, Inc. ............................................................................................................................................................................... 211
    BioStar Pharmaceuticals, Inc..................................................................................................................................................... 212
    Cornerstone Therapeutics Inc. .................................................................................................................................................. 213
    Acetylon Pharmaceuticals, Inc................................................................................................................................................... 214
    Trillium Therapeutics Inc. .......................................................................................................................................................... 215
    SBI Biotech Co., Ltd. ................................................................................................................................................................. 216


Rheumatoid Arthritis – Pipeline Review, H1 2012                                                                                           GMDHC1731IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                 Page(5)
Rheumatoid Arthritis – Pipeline Review, H1 2012




    CBio Limited .............................................................................................................................................................................. 217
    VentiRx Pharmaceuticals, Inc. ................................................................................................................................................... 218
    KaloBios Pharmaceuticals, Inc. ................................................................................................................................................. 219
    AB Science ................................................................................................................................................................................ 220
    Resolvyx Pharmaceuticals, Inc .................................................................................................................................................. 221
    OncoImmune, Inc. ..................................................................................................................................................................... 222
    Avesthagen Limited ................................................................................................................................................................... 223
    Nuon Therapeutics, Inc. ............................................................................................................................................................ 224
    KAHR medical Ltd. ........................................................................................................................
								
To top